Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)

Charles W Lynde, Maryam S Alam, Kamal Ohson, Angélique Gagné-Henley, Miriam Avadisian, Ronald B Vender, Charles W Lynde, Maryam S Alam, Kamal Ohson, Angélique Gagné-Henley, Miriam Avadisian, Ronald B Vender

Abstract

Introduction: Real-world evidence is important for post-marketing evaluation. Data comparing adalimumab's effectiveness and safety with traditional therapies in clinical settings are currently lacking. The aim of this study was to compare real-world effectiveness of adalimumab versus topical/traditional systemic agents for management of moderate to severe plaque psoriasis METHODS: Patients requiring change in treatment were enrolled between 2011 and 2016 and followed per routine care for up to 24 months. Achievement of Physician Global Assessment (PGA) ≤ 1.0 at 6 months was assessed with logistic regression; time to achievement was assessed using Cox regression. Additional outcomes were assessed using repeated measures mixed models.

Results: Patients receiving adalimumab (n = 293) versus topical/traditional systemic agents (n = 302) were more likely to achieve PGA ≤ 1.0 at 6 months (odds ratio 2.37, 95% confidence interval [CI] 1.31-4.30) in a shorter time (hazard ratio 2.14, 95% CI 1.53-3.00), reporting both lower body surface area and improved quality of life and work productivity.

Conclusion: In this real-world study, adalimumab was more effective than topical/traditional systemic agents at reducing disease activity and improving quality of life outcomes among Canadians with moderate to severe plaque psoriasis. (NCT00799877).

Keywords: Adalimumab; Canada; Dermatology; Effectiveness; Observational; Psoriasis; Topical; Traditional systemic.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Percentages of patients with moderate to severe plaque psoriasis achieving Physician Global Assessment ≤ 1.0 over time. Asterisk (*)Calculated based on a generalized estimating equation regression model. Percentages are based on patients with available information. CI Confidence interval, OR odds ratio

References

    1. Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E. Biological therapy of psoriasis. Indian J Dermatol. 2010;55(2):161–70. doi: 10.4103/0019-5154.62754.
    1. MedlinePlus. Psoriasis, . Accessed 5 Oct 2021.
    1. AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis—comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566–71. doi: 10.1111/ijd.14864.
    1. Canadian Dermatology Association. Psoriasis. 2021. . Accessed 5 Oct 2021.
    1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi: 10.1016/j.jaad.2013.11.013.
    1. Eder L, Widdifield J, Rosen CF, et al. Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken) 2019;71(8):1084–1091. doi: 10.1002/acr.23743.
    1. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. 2009. . Accessed 5 Oct 2021.
    1. Canadian Psoriasis Guidelines Addendum, C. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009. J Cutan Med Surg. 2016;20(5):375–431. doi: 10.1177/1203475416655705.
    1. Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668. doi: 10.3389/fimmu.2018.01668.
    1. Freiman A, Barankin B. Psoriasis. CMAJ. 2013;185(3):E174. doi: 10.1503/cmaj.090631.
    1. Canadian Psoriasis Network. Biologics and Biosimilars. 2020. . Accessed 24 Feb 2021.
    1. Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018;9(8):147–158. doi: 10.1177/2040622318772705.
    1. AbbVie Corporation. Product monograph. Humira (Adalimumab). . Appearance to 21 April 2021. Accessed 5 Oct 2021.
    1. Saurat J-H, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol. 2008;158(3):558–566. doi: 10.1111/j.1365-2133.2007.08315.x.
    1. Menter A, Thaçi D, Wu JJ, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb) 2017;7(3):365–381. doi: 10.1007/s13555-017-0198-x.
    1. Guan X, Zhang CL. An update on clinical safety of adalimumab in treating psoriasis: a systematic review and meta-analysis based on 20 randomized controlled trials. J Cosmet Dermatol. 2019;18:1550–1559. doi: 10.1111/jocd.12868.
    1. Mahil SK, Wilson N, Dandet N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) Br J Dermatol. 2020;182(5):1158–1166. doi: 10.1111/bjd.18333.
    1. Wu AG, Conway J, Barazani L, Roy B, Cline A, Pereira F. Is clear always clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in psoriasis clearance. Dermatol Ther (Heidelb) 2020;10(5):1155–63. doi: 10.1007/s13555-020-00435-2.
    1. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–51. doi: 10.1016/j.jaad.2010.12.005.
    1. Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Adalimumab efficacy in patients with psoriasis who received or did not respond to prior systemic therapy: a pooled post hoc analysis of results from three double-blind, placebo-controlled clinical trials. Am J Clin Dermatol. 2016;17(1):79–86. doi: 10.1007/s40257-015-0161-5.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj